<article xmlns="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle http://dtd.nlm.nih.gov/2.0/xsd/archivearticle.xsd" article-type="other">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Microbes Infect</journal-id>
      <journal-title-group>
        <journal-title>Microbes and Infection / Institut Pasteur</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1286-4579</issn>
      <issn pub-type="epub">1769-714X</issn>
      <publisher>
        <publisher-name>Elsevier</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">2832755</article-id>
      <article-id pub-id-type="pmid">20004735</article-id>
      <article-id pub-id-type="publisher-id">MICINF3522</article-id>
      <article-id pub-id-type="doi">10.1016/j.micinf.2009.12.001</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Immune responses to Epstein–Barr virus: molecular interactions in the virus evasion of CD8<sup>+</sup> T cell immunity</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Rowe</surname>
            <given-names>Martin</given-names>
          </name>
          <email>m.rowe@bham.ac.uk</email>
          <xref rid="cor1" ref-type="corresp">∗</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zuo</surname>
            <given-names>Jianmin</given-names>
          </name>
        </contrib>
      </contrib-group>
      <aff>Cancer Research UK Birmingham Cancer Centre, University of Birmingham, College of Medical and Dental Sciences, Vincent Drive, Edgbaston, Birmingham B15 2TT, United Kingdom</aff>
      <author-notes>
        <corresp id="cor1"><label>∗</label>Corresponding author. <email>m.rowe@bham.ac.uk</email></corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <month>3</month>
        <year>2010</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="ppub"/>. -->
      <pub-date pub-type="ppub">
        <month>3</month>
        <year>2010</year>
      </pub-date>
      <volume>12</volume>
      <issue>3</issue>
      <fpage>173</fpage>
      <lpage>181</lpage>
      <history>
        <date date-type="received">
          <day>24</day>
          <month>11</month>
          <year>2009</year>
        </date>
        <date date-type="accepted">
          <day>1</day>
          <month>12</month>
          <year>2009</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2010 Elsevier Masson SAS.</copyright-statement>
        <copyright-year>2009</copyright-year>
        <copyright-holder>Elsevier Masson SAS</copyright-holder>
        <license>
          <license-p>This document may be redistributed and reused, subject to <ext-link ext-link-type="uri" xlink:href="http://www.elsevier.com/wps/find/authorsview.authors/supplementalterms1.0">certain conditions</ext-link>.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Persistent viruses have mechanisms for modulating the host immune responses that are essential for achieving a lifelong virus–host balance while minimizing the viral pathogenicity. Here we review some of the immune-modulating mechanisms evolved by the ubiquitous but potentially oncogenic Epstein–Barr virus, with particular emphasis on the molecular mechanisms of genes interfering with HLA class I antigen presentation.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Epstein–Barr virus</kwd>
        <kwd>Immune-evasion</kwd>
        <kwd>Antigen presentation</kwd>
        <kwd>Tumour virus</kwd>
        <kwd>Herpesvirus</kwd>
        <kwd>Immune response</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="sec1">
      <label>1</label>
      <title>Introduction</title>
      <p>Persistent viruses are pathogens that co-exist in balance with and for the life of their immunocompetent hosts, often without causing any symptoms. This delicate virus–host balance can be upset by perturbation of the immune responses, or through genetic or environmental factors. Indeed, persistent viruses are a major worldwide source of morbidity and mortality, responsible for diverse pathologies ranging from virus-associated cancers to life-threatening virus replicative infections in the immunocompromised. Epstein–Barr virus (EBV), which is carried by more that 90% of the adult human population worldwide, is a prime example of a persistent virus that is generally harmless, but which can cause serious diseases.</p>
      <p>EBV is a γ<sub>1</sub>-herpesvirus that replicates in permissive cells in the oropharynx but persists as a latent infection in long-lived memory B lymphocytes. Primary infection with EBV transmitted by salivary transfer is usually clinically silent but can manifest as infectious mononucleosis (IM), a self-limiting lymphoproliferative disease caused by excessive but ineffective T cell responses to EBV-infected B cells <xref rid="bib1" ref-type="bibr">[1]</xref>. As the mononucleosis resolves, effective CD8<sup>+</sup> and CD4<sup>+</sup> T cell responses become established and the virus:host homeostasis is achieved.</p>
      <p>The importance of the host T cell surveillance for preventing EBV pathogenesis is well-illustrated by the increased incidence of potentially fatal lymphoproliferative lesions in patients receiving immunosuppressive therapy following organ transplants, which can be reversed by infusion of EBV-specific immune T cells <xref rid="bib2 bib3" ref-type="bibr">[2,3]</xref>. These lesions comprise EBV-transformed B cells, which are phenotypically similar to lymphoblastoid cell lines (LCL) that are easily established following experimental infection of resting B cells with EBV <italic>in vitro</italic>. The growth-transformed LCL generally sustain a non-permissive infection with expression of a limited number of so-called latent genes. The viral genes expressed in LCL encode six nuclear proteins (EBNA-1, EBNA-2, EBNA3A, EBNA-3B, EBNA-3, EBNA-LP), four membrane proteins (LMP1, LMP2A, LMP2B, and BHRF1) and various non-coding RNAs <xref rid="bib4" ref-type="bibr">[4]</xref>. These transformation-associated genes act co-operatively on the cell to enhance cell survival and proliferation (reviewed in <xref rid="bib4 bib5" ref-type="bibr">[4,5]</xref>). In this fundamental respect, EBV differs from human α-herpesviruses (e.g. herpes simplex, HSV) and β-herpesviruses (e.g. human cytomegalovirus, HCMV) in amplifying the viral load in the infected host by replicating itself via cell proliferation-associated duplication of the viral genome, in addition to the lytic cycle virus replication displayed by all herpesviruses.</p>
    </sec>
    <sec id="sec2">
      <label>2</label>
      <title>EBV latency <italic>in vivo</italic></title>
      <p>In normal persistent infection of the healthy host, the EBV genomes in the resting memory B cell compartment are mostly transcriptionally silent (reviewed, <xref rid="bib4 bib6" ref-type="bibr">[4,6]</xref>). The potential for these EBV genomes to be reactivated to express the growth-transformation-associated genes poses the risk of oncogenesis. Indeed, EBV is associated with several tumours of B cell origin, and also other cell types, including: post-transplant lymphoproliferative disease, Burkitt's lymphoma, Hodgkin's lymphoma, T/NK cell lymphomas, nasopharyngeal carcinoma, and gastric carcinoma (reviewed <xref rid="bib5" ref-type="bibr">[5]</xref>). One strategy employed by the virus to limit the extent and consequences of EBV-induced cell proliferation in the immunocompetent host, is to link growth-transformation to immunogenicity. Thus, the LMP1 viral oncoprotein, which displays signalling functions similar to a constitutively active receptor of the CD40/TNFR family, has oncogenic potential by enhancing cell survival through upregulation of anti-apoptotic cellular proteins, but it also upregulates components of the antigen processing pathways to enhance presentation of viral target epitopes to CD4<sup>+</sup> and CD8<sup>+</sup> immune T cells <xref rid="bib7" ref-type="bibr">[7]</xref>. In addition, the transformation-associated viral proteins (most notably the EBNA-3A, -3B, and-3C family of nuclear proteins) are themselves the source of several immunodominant target epitopes for the T cell immune responses (reviewed, <xref rid="bib8" ref-type="bibr">[8]</xref>).</p>
      <p>In immunocompetent and asymptomatically infected hosts, direct evidence of EBV-infected B cells expressing a growth-transformed phenotype is rarely found. Such cells are, however, observed in tonsils of IM patients where ineffective immune responses allow limited outgrowth of EBV-transformed lymphoblastoid cells <xref rid="bib9" ref-type="bibr">[9]</xref>. Indirect evidence for expression of the growth-transforming genes in immunocompetent hosts is provided by the invariable presence of antibodies, CD4<sup>+</sup> T cells, and CD8<sup>+</sup> T cells with specificity for one or more of these proteins (reviewed, <xref rid="bib5 bib8" ref-type="bibr">[5,8]</xref>). It is presumed, therefore, that growth-transformed B cells must be present in sufficient numbers to continuously stimulate and maintain the immune responses which, while not able to eliminate EBV completely from the host, are usually sufficient to prevent the outgrowth of potentially cancerous cells.</p>
      <p>How is it that EBV is never eliminated? One possibility is that the original virus infection does not actually persist for life, but that the host is periodically re-infected by virus from other infected individuals. Arguing against this possibility is the observed persistence and dominance of a single virus isolate in many individuals screened for more than 15 years <xref rid="bib10" ref-type="bibr">[10]</xref>. Current opinions on the mechanism of EBV persistence differ in certain details <xref rid="bib5 bib11" ref-type="bibr">[5,11]</xref>, but it is generally agreed that expansion of infected B cell numbers in immunocompetent hosts occurs in the secondary lymphoid tissues, and that some of the growth-transformed cells must revert to a more restricted form of latency, ultimately in memory B cells and before re-entering the periphery, in order to escape immune T cell responses. Consistent with this view, analysis of EBV-infected cells in the peripheral blood reveals that the virus is confined to the memory B cell population and that none of the transformation-associated proteins is expressed; the EBV genome is either silent or restricted to non-coding RNA transcripts (reviewed, <xref rid="bib4 bib5 bib6" ref-type="bibr">[4–6]</xref>). These latently infected cells are, therefore, immunologically silent. Even in immunosuppressed individuals prone to lymphoproliferative disease, the elevated viral load in the blood is due to an increased number of immunologically silent, latently infected resting memory B cells rather than to the presence of growth-transformed or lytically infected cells <xref rid="bib12" ref-type="bibr">[12]</xref>.</p>
    </sec>
    <sec id="sec3">
      <label>3</label>
      <title>EBV lytic replication <italic>in vivo</italic></title>
      <p>Whilst EBV differs from α- and β-herpesviruses in its ability to growth-transform cells in culture and in its causative role in cancers, in other respects it is a typical herpesvirus, particularly with regards to the generation of new infectious virus progeny though the lytic cycle. The major site of lytic EBV replication is in the oropharynx, where infectious virus is detected in the saliva.</p>
      <p>It is not certain precisely where, or in what cells, does lytic replication normally occur. As is often the case, lessons from pathological states have been applied to construct hypotheses on the mechanisms of asymptomatic persistence. Superficially, EBV appears to be lymphotrophic <italic>in vitro</italic> as a result of the restricted expression of CD21, the cellular receptor for the gp350 viral envelope glycoprotein <xref rid="bib5" ref-type="bibr">[5]</xref>. Nevertheless, the presence of EBV in oral hairy leukoplakia of AIDS patients and in nasopharyngeal carcinoma and gastric carcinoma clearly shows that infection of epithelial cells is possible <italic>in vivo</italic>. The question is, whether infection of epithelial cells is a normal part of EBV persistence, or whether it is a rare event associated with pathogenesis. In fact, it is now known that very efficient infection of epithelial cells can be achieved <italic>in vitro</italic> following binding of EBV to CD21 on B cells and transfer via conjugates formed between the virus-loaded B cells and epithelial cells, or by conjugates formed between lytically infected B cells and epithelial cells <xref rid="bib13" ref-type="bibr">[13]</xref>. This is consistent with the view that infection of epithelial cells is a normal feature of asymptomatic persistence in the infected host, which might only rarely give rise to pathogenic lesions. In Hairy Leukoplakia, the lesions on the tongue or in the oral cavity were characterized by foci of extensive lytic virus production in differentiating epithelial cells <xref rid="bib14" ref-type="bibr">[14]</xref>. This paralleled observations on other viruses, e.g. papilloma viruses, where latent infection in the basal epithelium progressed to lytic virus replication in the upper, more differentiated layers.</p>
      <p>From this background, the idea was promulgated that EBV normally persists as a latent infection of B cells, but that lytic virus replication occurs in epithelial cells of the oropharynx <xref rid="bib5" ref-type="bibr">[5]</xref>. The problem is that EBV lytic cycle in epithelial cells has only rarely been demonstrated in tissues from immunocompetent individuals. Furthermore, if persistence in the B cell compartment serves any purpose, the virus must be able to escape from the B cell. It is a reasonable presumption that at some point, latently infected B cells might be reactivated into lytic cycle. If this were to occur in tissues in the oropharynx, then the virus progeny might represent that virus which is detected in the saliva of healthy immunocompetent individuals. Alternatively, the virus produced in the B cells may infect epithelial cells as an amplification step for enhanced virus production. As with epithelial cells, however, convincing demonstration of lytically infected B cells in tissues from immunocompetent individuals is rare. The most reliable reported studies have been on tonsils, which are assumed to be the site of virus entry during primary infection. Nevertheless, only occasional lytically infected cells have been observed in tonsil tissues, most often in lymphoid cells and very rarely in epithelial cells <xref rid="bib15 bib16" ref-type="bibr">[15,16]</xref>. It is possible that the majority of lytic EBV replication occurs not in the tonsil, but elsewhere in the oropharynx.</p>
      <p>Whilst the nature of EBV latency <italic>in vivo</italic> is relatively well understood, there are significant gaps in the experimental evidence supporting the models of lytic EBV replication in the healthy immunocompetent host.</p>
    </sec>
    <sec id="sec4">
      <label>4</label>
      <title>Immune responses to lytic EBV proteins</title>
      <p>In excess of 80 EBV proteins are expressed during lytic virus replication <xref rid="bib17" ref-type="bibr">[17]</xref>. Activation of lytic cycle from latency is initiated by expression of two immediate-early proteins encoded by the <italic>BZLF1</italic> and <italic>BRLF1</italic> genes. Their Zta and Rta protein products are transcription factors which activate a cascade of viral gene transcription, starting with several early genes after about 2 h, followed by delayed early and late genes from about 4 h onwards. Maximum expression of late proteins, including structural viral capsid antigens (VCA) and envelope glycoproteins, is achieved within about 12 h after Zta and Rta expression <xref rid="bib17 bib18" ref-type="bibr">[17,18]</xref>. Although virus release can be detected within 24 h, cells in lytic cycle can actually survive several days <italic>in vitro</italic> before dying <xref rid="bib19" ref-type="bibr">[19]</xref>. Consequently, there is considerable opportunity <italic>in vivo</italic> for mounting effective immune responses to lytic cycle proteins to limit infectious virus production. As with other herpesvirus infections, the host mounts vigorous humoral and cellular immune responses to many lytic cycle antigens. Serum IgG antibodies to VCA are reliable indicators of the EBV carrier status of healthy infected individuals. Serum IgA antibodies to VCA and/or early antigens can be diagnostic for nasopharyngeal carcinoma; this is often interpreted as reflecting the mucosal origin of this EBV-associated tumour <xref rid="bib5" ref-type="bibr">[5]</xref>. However, the emerging tumours are usually VCA-negative, and the IgA response is therefore most likely stimulated by lytic cycle activation in non-tumour cells at mucosal sites in these patients. Serum IgA antibodies to lytic cycle antigens are also generated during primary infection IM patients, again indicating lytic virus production in mucosal sites <xref rid="bib20" ref-type="bibr">[20]</xref>.</p>
      <p>T cell responses to lytic cycle antigens represent a dominant fraction of the EBV-specific T cells generated during primary EBV infection manifest as IM <xref rid="bib8" ref-type="bibr">[8]</xref>. Whilst some of these lytic antigen responses disappear with resolution of the disease, responses to some lytic cycle antigens still represent a significant proportion of the EBV-specific T cell responses in the normal persistent carrier-state. Interestingly, however, the primary CD8<sup>+</sup> responses to EBV lytic cycle antigens show a skewed immunodominance for the immediate-early and early antigens, with remarkably few responses detected to late lytic cycle antigens <xref rid="bib21" ref-type="bibr">[21]</xref>. This is now thought to reflect the existence of, and temporal expression of viral immune-evasion genes. Three such genes (<italic>BNLF2a, BGLF5, BILF1</italic>) were recently demonstrated to directly interfere with the HLA-I antigen presentation pathway to modulate the CD8<sup>+</sup> immune responses to EBV, and the molecular functions of these genes will be discussed in more detail in the next section.</p>
      <p>The EBV <italic>BCRF1</italic> late gene encodes a vIL-10 cytokine that has also been shown to downregulate cell surface HLA-1 through transcriptional inhibition of TAP-1 expression, although whether this actually impacts on T cell recognition of endogenous antigen was not tested <xref rid="bib22" ref-type="bibr">[22]</xref>. The vIL-10 homologue shares some of the properties of the human IL-10 cytokine, and its effects on the immune system are multiple and complex. Indeed, vIL-10 has also been reported to stimulate the reactivation of anti-EBV T cell responses <xref rid="bib23" ref-type="bibr">[23]</xref>. The EBNA1 nuclear protein, which is expressed both in latent and lytic forms of infection <xref rid="bib17" ref-type="bibr">[17]</xref>, is also able to interfere with antigen presentation although the mode of action is conceptually distinct from BNLF2a, BGLF5, BILF1, and vIL-10 in that it only affects the processing of antigenic peptides from the EBNA1 protein itself. This unusual mechanisms is the result of a large repetitive region in the <italic>EBNA1</italic> gene encoding a Gly-Ala repeat domain comprising about one-third of the EBNA1 protein, which interferes with proteasomal degradation of the EBNA1 polypeptide <xref rid="bib24" ref-type="bibr">[24]</xref>.</p>
      <p>Modulation of CD4+ immune responses has been less well studied. Nevertheless, downregulation of HLA class II (HLA-II) transcripts by the Zta immediate-early protein <xref rid="bib25" ref-type="bibr">[25]</xref> and the BGLF5 early viral protein <xref rid="bib26" ref-type="bibr">[26]</xref>, together with the steric interference with T cell receptor (TCR) recognition by physical association of the late viral BZLF2 protein (gp42) with HLA-II protein complexes <xref rid="bib27 bib28" ref-type="bibr">[27,28]</xref>, indicate that EBV has likewise evolved mechanisms to interfere with the HLA-II antigen presentation pathway.</p>
      <p>There is also evidence that EBV lytic cycle gene products can evade anti-viral interferon responses. For example, the immediate-early Zta protein inhibits IFNγ-receptor expression by the infected cell <xref rid="bib29" ref-type="bibr">[29]</xref>. This might directly impact on T cell recognition of lytic cells because one of the functions of interferons is to upregulate expression of HLA-I, HLA-II, adhesion molecules, and other components of the antigen presentation pathways.</p>
    </sec>
    <sec id="sec5">
      <label>5</label>
      <title>Modulation of the HLA-I antigen presentation pathway by EBV lytic cycle proteins</title>
      <p>The HCMV and murine CMV β-herpesviruses have become paradigms for viral interference with the HLA class-I (HLA-I) antigen presentation pathway (reviewed <xref rid="bib30 bib31" ref-type="bibr">[30,31]</xref>). HCMV, for example, encodes at least 4 proteins that interfere with HLA-I antigen presentation at multiple points in the pathway from proteasomal degradation of target proteins through to peptide transport to the endoplasmic reticulum, formation of peptide/HLA-I/β<sub>2</sub>-microglobulin trimeric complexes in the endoplasmic, and transport to the cell surface for presentation to the TCR of CD8<sup>+</sup> T cells (see <xref rid="fig1" ref-type="fig">Fig. 1</xref>A). The HCMV early protein, US6, inhibits peptide transport to the endoplasmic reticulum via the peptide transporter (TAP-1/TAP-2) complex, and early or late proteins affect HLA-I maturation either by retaining these molecules in the ER (US3), or inducing their retrograde transport to cytosol for proteasomal degradation (US2, US11).</p>
      <p>Many other examples of interference with the HLA-I presentation pathway by viruses other than CMV have also been identified (reviewed, <xref rid="bib31" ref-type="bibr">[31]</xref>). The search for equivalent mechanisms by EBV was initiated following the demonstration that EBV-infected B cells in lytic cycle showed downregulation of cell surface HLA class I expression that was at least in part due to impaired TAP-1/TAP-2 peptide transport function and to a hitherto unknown host protein-synthesis shutoff function <xref rid="bib19 bib32 bib33" ref-type="bibr">[19,32,33]</xref>. Subsequently, the identification of at least three EBV proteins that limit the visibility of lytically infected cells to CD8<sup>+</sup> T cells suggested that EBV has similar strategies to CMV for interfering with HLA-I antigen presentation, although they differ in the detail of individual molecular mechanisms (<xref rid="fig1" ref-type="fig">Fig. 1</xref>B). The current knowledge of the molecular functions of the BNLF2a, BGLF5 and BILF1 proteins will now be summarized:</p>
    </sec>
    <sec id="sec6">
      <label>6</label>
      <title>BNLF2a</title>
      <p>The immune-evasion function of BNLF2a was first identified through a targeted strategy based on the reasoning that such functions were most likely to map to genes unique to the γ<sub>1</sub>-herpesvirus genus <xref rid="bib34" ref-type="bibr">[34]</xref>. Interestingly, of the 11 EBV genes unique to γ<sub>1</sub>-herpesviruses of Old World primates, at least 4 are now known to have immune-modulatory functions: the <italic>BARF1</italic> gene encodes a secreted protein able to bind Colony-Stimulating Growth Factor-1 and thereby inhibit macrophage activation <xref rid="bib35" ref-type="bibr">[35]</xref>; the gp42 product of the <italic>BZLF2</italic> gene associates with MHC-II molecules to inhibit recognition by the TCR of EBV-specific CD4<sup>+</sup> T cells <xref rid="bib27 bib28" ref-type="bibr">[27,28]</xref>; <italic>BILF1</italic> encodes a vGPCR that targets HLA-I molecules for degradation (see below); and <italic>BNLF2a</italic> encodes a small, 60 amino acid residue membrane protein that localizes to the endoplasmic reticulum and physically associates with the TAP complex <xref rid="bib34 bib36" ref-type="bibr">[34,36]</xref>.</p>
      <p>BNLF2a effects downregulation of cell surface HLA-I molecules and impairment of antigen presentation to CD8<sup>+</sup> effectors by inhibiting peptide transport to the ER lumen via TAP <xref rid="bib34" ref-type="bibr">[34]</xref>. Normal translocation of antigenic peptides from the cytosol to the ER via the TAP complex is initiated by the binding of peptides to cytosolic domains of TAP, followed by the binding and hydrolysis of ATP which promotes the opening of a transmembrane pore through which the peptides are then pumped. BNLF2a acts by binding TAP and inhibiting both peptide and ATP binding to TAP, thus efficiently blocking peptide transport <xref rid="bib34 bib36" ref-type="bibr">[34,36]</xref>. BNLF2a therefore adds to a growing list of herpesvirus proteins that inhibit TAP function, although its mechanism of action differs from those previous identified. For example, the US6 protein of HCMV binds to an ER luminal loop of TAP and signals across the ER membrane to inhibit ATP binding to the cytosolic domain of TAP, thus inhibiting ATP hydrolysis but not affecting the ability of peptides to bind TAP <xref rid="bib37" ref-type="bibr">[37]</xref>. Conversely, the ICP47 proteins of HSV-1 and -2 efficiently compete for peptide binding to TAP without affecting ATP binding <xref rid="bib38 bib39" ref-type="bibr">[38,39]</xref>, while the UL49.5 gene product of Bovine herpesvirus-1 affects neither peptide nor ATP binding to TAP, but still abrogates the peptide transport function and ultimately targets both TAP-1 and TAP-2 for degradation <xref rid="bib40 bib41" ref-type="bibr">[40,41]</xref>.</p>
      <p>The binding of BNLF2a to TAP appears to stabilize expression of the viral protein since its expression levels in model cell lines devoid of TAP are substantially reduced, although the ER membrane localization of the residual BNLF2a remains unchanged <xref rid="bib36" ref-type="bibr">[36]</xref>. Remarkably, however, during EBV lytic cycle in TAP-expressing B cells the levels of BNLF2a protein peak at around 6 h after induction of lytic cycle, thereafter declining rapidly to barely detectable levels by 12 h despite an only modest decrease in BNLF2a transcripts in this time-frame <xref rid="bib18" ref-type="bibr">[18]</xref>. The mechanisms underlying this transient expression of BNLF2a protein during lytic cycle are unknown, but the implications for the immune-evasion strategy of EBV have been investigated. Thus, CD8+ T cell recognition of immediate-early and early EBV proteins in lytically infected B cells carrying a BNLF2a-deleted recombinant EBV was enhanced relative to recognition of those targets in lytically infected B cells carrying a wild-type EBV genome; in contrast deletion of BNLF2a did not enhance recognition of late lytic cycle antigen targets <xref rid="bib18" ref-type="bibr">[18]</xref>. This fits with the transient nature of the BNLF2a protein expression, which declines as late lytic cycle proteins are expressed, and indicates that additional immune-evasion genes come into play as lytic cycle progresses. <italic>BGLF5</italic> and <italic>BILF1</italic> are two such genes.</p>
    </sec>
    <sec id="sec7">
      <label>7</label>
      <title>BGLF5, a dual-function protein</title>
      <p>The product of the <italic>BGLF5</italic> gene was originally identified as a DNase enzyme <xref rid="bib42" ref-type="bibr">[42]</xref>, which is homologous to the alkaline exonucleases that are highly conserved in all herpesviruses. These DNases are early lytic cycle genes, and they are critically required for efficient processing of the viral genome, as was originally shown for HSV-1 where <italic>nuc</italic> mutations in the <italic>UL12</italic> DNase gene resulted in a 10<sup>−2</sup> to 10<sup>−3</sup> reduction in infectious virus titres following lytic replication <xref rid="bib43 bib44" ref-type="bibr">[43,44]</xref>. The <italic>BGLF5</italic> gene is likewise essential for efficient infectious virus production, being required for optimal viral DNA synthesis, genome encapsidation, and nuclear egress of the virus <xref rid="bib45" ref-type="bibr">[45]</xref>.</p>
      <p><italic>In vitro</italic>, herpesvirus DNases accept both double-stranded and single-stranded DNA as substrates, and they function optimally at alkaline pH in the presence of Mg<sup>++</sup> divalent ions. They preferentially show 5′–3′ exonuclease activity, although weaker 3′–5′ exonuclease and endonuclease activities have also been observed. Sequence alignment of DNase proteins from several different herpesviruses first indicated 7 conserved motifs <xref rid="bib46" ref-type="bibr">[46]</xref> and subsequent molecular modeling and phylogenetic analyses suggested that herpesvirus DNases belong to a restriction endonuclease superfamily characterized by a catalytic core motif, PD-(D/E)XK <xref rid="bib47" ref-type="bibr">[47]</xref>. Site-directed mutagenesis of these defining residues in BGLF5 confirmed their importance for the alkaline DNase activity <xref rid="bib48" ref-type="bibr">[48]</xref> and, more recently, the crystal structure of BGLF5 was determined to 3 Å resolution to confirm and greatly extend the details of these structure–function observations <xref rid="bib49" ref-type="bibr">[49]</xref>.</p>
      <p>The alkaline DNase function of the EBV gene is therefore well established. However, a second less well understood function of this molecule was recently identified: a host protein-synthesis shutoff function which operates at the level of mRNA transcripts <xref rid="bib26" ref-type="bibr">[26]</xref>. The identification of this second function for BGLF5 followed an earlier observation from the Ganem group that the DNase encoded by the <italic>ORF37</italic> gene of KSHV had dual host-shutoff and exonuclease functions; hence, the ORF37 protein was designated SOX <xref rid="bib50" ref-type="bibr">[50]</xref>. In both BGLF5 <xref rid="bib51" ref-type="bibr">[51]</xref> and SOX <xref rid="bib52" ref-type="bibr">[52]</xref> proteins the exonuclease and host-shutoff functions are genetically separable. Furthermore, both BGLF5 and SOX were found to decrease expression of HLA-I molecules at the cell surface and to reduce antigen presentation to CD8<sup>+</sup> effector T cells. This immune-evasion function mapped to the host-shutoff activity rather than to the exonuclease activity <xref rid="bib51" ref-type="bibr">[51]</xref>.</p>
      <p>An additional shutoff function appears to be a feature of the DNases of the γ-herpesvirus genus <xref rid="bib53" ref-type="bibr">[53]</xref>. In α-herpesviruses a host-shutoff function is mediated by a separate protein, typified by the <italic>UL41</italic> vhs protein of HSV-1, which is expressed as a late lytic cycle antigen and induces host-shutoff via an intrinsic RNase activity. Interestingly, the HSV-1 vhs protein has been shown to reduce expression of HLA-I, HLA-II, and several pro-inflammatory cytokines (reviewed in <xref rid="bib54" ref-type="bibr">[54]</xref>). While BGLF5 and SOX similarly downregulate HLA-II as well as HLA-I <xref rid="bib26 bib51" ref-type="bibr">[26,51]</xref>, the extent of their immune-modulatory effects beyond impairing CD8+ T cell recognition has not yet been studied. The β-herpesviruses, do not encode any shutoff function, suggesting distinct evolutionary developments of DNase and host-shutoff functions in the three main herpesviruses families. Indeed, extensive phylogenetic analysis indicates that α- and β-herpesvirus DNases are more closely related to λ-bacteriophage DNase, while the DNases of γ-herpesviruses with acquired of host-shutoff function represent a more recent evolutionary divergence <xref rid="bib47" ref-type="bibr">[47]</xref>.</p>
      <p>What is the mechanistic basis of the host-shutoff function of γ-herpesviruses DNases? Initially, it was thought that neither EBV-BGLF5 nor KSHV SOX had intrinsic RNase activity, indicating that their effect on global mRNA levels was mediated via modulation of cellular mRNA turnover pathways. With regards to the γ<sub>2</sub>-herpesviruses, KSHV and murine herpesvirus 68, the host-shutoff function of their SOX proteins appears to involve hyperadenylation of the poly-A tails of nascent cellular RNAs, promotion of their retention in the nucleus, together with a relocalization of a cytoplasmic poly-A binding protein to the nucleus, leading to instability of cytoplasmic mRNAs <xref rid="bib53 bib55" ref-type="bibr">[53,55]</xref>. Furthermore, the recently resolved crystal structure of KSHV SOX shows that point-mutations specifically affecting the shutoff function mostly map away from the DNase catalytic core and are clustered at the surface of the protein, away from the catalytic core <xref rid="bib56" ref-type="bibr">[56]</xref>. Dahlroth and colleagues have speculated that this surface region might be a point of interaction with cellular proteins or RNA.</p>
      <p>A recent study by Buisson and colleagues, in which they resolved the crystal structure of BGLF5, indicates an additional mechanism of host-shutoff. An intrinsic RNase activity was observed in the presence of Mn<sup>++</sup> ions, rather than the Mg<sup>++</sup> ions preferred for DNase activity, which degraded unstructured mRNA but not structured tRNA <xref rid="bib49" ref-type="bibr">[49]</xref>. This RNase activity was due to a 5′–3′ exonuclease activity, and was abrogated by a D203S mutation in the essential catalytic core motif (D203 …. E225-X-K227) of DNase activity. The <italic>in vivo</italic> significance of this intrinsic RNase activity, which may be up to 2 orders of magnitude weaker than the DNase activity <italic>in vitro</italic>, remains to be determined, particularly since it is not known whether the intracellular concentration of Mn<sup>++</sup> ions is sufficient for RNase activity. At the time of writing this review, it is not known whether the γ<sub>2</sub>-herpesvirus SOX proteins share this Mn<sup>++</sup>-dependent RNase activity. There are, however, some indications that BGLF5 might differ from the γ<sub>2</sub>-herpesvirus SOX proteins in the mechanistic details of host-shutoff function. Thus, our attempts to extrapolate from the mutational studies on KSHV SOX <xref rid="bib52" ref-type="bibr">[52]</xref> to engineer a mutant BGLF5 that selectively lost either DNase or shutoff function were unsuccessful (Zuo &amp; Rowe, unpublished). Random mutagenesis of BGLF5 resulted in the generation of 67 mutants in which both DNase and shutoff function were impaired, but only one mutant (S280L) that was selectively impaired for DNase activity and another (K231M) that was selectively impaired for shutoff function <xref rid="bib51" ref-type="bibr">[51]</xref>. In contrast, random mutagenesis of the KSHV SOX protein gave rise to 6 mutants with selective loss of shutoff function, one with selective loss of DNase function and about 20 with double loss of function (Dr Britt Glaunsinger, personal communication, and <xref rid="bib52" ref-type="bibr">[52]</xref>). Furthermore, whereas the SOX mutations that selectively impaired shutoff function mostly localized to an area of surface away from the catalytic core <xref rid="bib56" ref-type="bibr">[56]</xref>, the K231 residue of BGLF5 locates to the edge of the DNase catalytic canyon (<xref rid="fig2" ref-type="fig">Fig. 2</xref>). While these data do not rule out the possibility of additional protein–protein interactions in the N-terminus region of BGLF5, they do point to the possibility of γ<sub>1</sub>- and γ<sub>2</sub>-herpesviruses having evolved distinct mechanisms for the acquisition of host-shutoff functions.</p>
    </sec>
    <sec id="sec8">
      <label>8</label>
      <title>BILF1, a viral G-protein-coupled receptor (vGPCR)</title>
      <p>Following a systematic screen of EBV lytic genes, <italic>BILF1</italic> was identified as a gene able to downregulate cell surface HLA-I expression, but not HLA-II, and to impair CD8<sup>+</sup> T cell recognition of endogenously-processed antigen <xref rid="bib57" ref-type="bibr">[57]</xref>. <italic>BILF1</italic> encodes a seven transmembrane spanning protein with structural and functional characteristics of a constitutively signalling vGPCR/chemokine receptor <xref rid="bib58 bib59" ref-type="bibr">[58,59]</xref>.</p>
      <p>All herpesviruses encode at least one vGPCR, and their role in viral lytic cycle is thought to be to reprogramme the host cell through multiple signaling pathways <xref rid="bib60 bib61" ref-type="bibr">[60,61]</xref>. Several vGPCRs have the potential to modulate the immune responses. For example, the US28 vGPCR of HCMV <xref rid="bib62" ref-type="bibr">[62]</xref> and the U51 vGPCR of HHV6 <xref rid="bib63" ref-type="bibr">[63]</xref> can modify the chemokine environment of infected cells by binding and internalizing MCP-1 (monocyte chemoattractant protein) and RANTES (regulated on activation, normal T cell expressed and secreted). In addition, the UL28 vGPCR of HCMV can transcriptionally regulate expression of MCP-1 <xref rid="bib64 bib65" ref-type="bibr">[64,65]</xref>, and the U51 vGPCR of HHV6 can transcriptionally regulate expression of RANTES <xref rid="bib63" ref-type="bibr">[63]</xref>. To date, however, BILF1 is the only human herpesvirus vGPCR shown to target the HLA-I antigen presentation pathway; a property shared by the closely related vGPCR of the CeHV15 γ<sub>1</sub>-herpesvirus of Rhesus Old World primates, with 80% amino acid sequence identity to EBV BILF1, but not by the most closely related human herpesvirus vGPCR encoded by the <italic>ORF74</italic> of KSHV, which has just 15% sequence identity with EBV BILF1 <xref rid="bib57" ref-type="bibr">[57]</xref>.</p>
      <p>Interestingly, downregulation of cell surface HLA-I expression can be induced by activation of the cellular CXCR4 GPCR by its CXCL12 ligand <xref rid="bib66" ref-type="bibr">[66]</xref>. Mechanistically, this process involves physical association of CXCR4 with the β<sub>2</sub>-microglobulin, ubiquitination of HLA-I heavy chain, and endocytosis followed by degradation <xref rid="bib66" ref-type="bibr">[66]</xref>. Superficially, this process is similar to BILF1 vGPCR-induced degradation of HLA-I in so much as BILF1 binds to the HLA-I/β<sub>2</sub>-microglobulin complex, accelerates loss of HLA-I molecules from the cell surface, and markedly reduces the half-life of HLA-I molecules <xref rid="bib57" ref-type="bibr">[57]</xref>. However, a signaling-defective mutant of BILF1 retains its ability to downregulate HLA-I expression, and there no is no evidence that BILF1 induces ubiquination of MHC class I heavy chains above the levels seen in control cells lacking BILF1, and neither is there evidence that BILF1 associates with HLA-I via interaction with β<sub>2</sub>-microglobulin <xref rid="bib57" ref-type="bibr">[57]</xref>. Nevertheless, it is notable that when co-expressed in the same cell BILF1 and CXCR4 show almost complete co-localization, both being predominantly localized to the plasma membrane, in contrast to KSHV-ORF74 and HCMV-US28 vGPCRs which exhibit a predominantly intracellular localization <xref rid="bib59" ref-type="bibr">[59]</xref>.</p>
      <p>Many other viral gene products, all of which are structurally unrelated to GPCRs, have been shown to target HLA-I molecules for degradation as strategies for impairing antigen presentation to CD8<sup>+</sup> T cells. They either induce endocytosis and lysosomal degradation of cell surface MHC class I complexes through RING-finger motif (e.g. the KSHV K3 and K5 proteins) or target MHC-I complexes for degradation through dileucine motifs in their cytosolic C-terminus (e.g. HIV-I nef, murine CMV gp48, and the HHV6 U21 proteins). The BILF1 vGPCR has neither a RING-finger motif nor dilucine motifs. However, our recent results with BILF1 mutants are consistent with the presence of C-terminus signal on the vGPCR which sorts HLA-I molecules on endosomes for degradation rather than recycling (Zuo and Rowe, unpublished). The HIV nef protein was one of the first viral proteins reported to induce endocytosis and degradation of HLA-I molecules from the cell surface <xref rid="bib67" ref-type="bibr">[67]</xref>, although more recent studies suggest that nef might act predominantly by diverting HLA-I molecules to endosomes/lysosomes before they reach the cell surface <xref rid="bib68 bib69 bib70" ref-type="bibr">[68–70]</xref>. Since BILF1 is predominantly located in the plasma membrane, and can promote endocytosis of HLA-I from the cell surface, the original hypothesis for the mechanism of action of BILF1 was that it promotes degradation of HLA-I via endocytosis and lysosomal degradation <xref rid="bib57" ref-type="bibr">[57]</xref>. Whilst this conclusion remains valid, our most recent data from mutant BILF1 proteins indicate that the mechanism of action of EBV vGPCR is more complex than was originally thought. Consistent with the fact that BILF1 can associate with immature HLA-I molecules in the ER shortly after synthesis <xref rid="bib57" ref-type="bibr">[57]</xref>, an additional mechanism of action might also involve diversion of HLA-I molecules for degradation before reaching the cell surface (Zuo and Rowe, unpublished).</p>
    </sec>
    <sec id="sec9">
      <label>9</label>
      <title>Conclusions</title>
      <p>That EBV has multiple proteins acting in concert on the HLA-I antigen pathway is significant in many respects. Firstly, it emphasizes that even when a herpesvirus has potent growth-transforming functions and the potential to cause cancer, the need for immune-modulating functions during its lytic replication stage is a paramount phenotype that unifies all herpesviruses. Secondly, it highlights the diversity of mechanisms that have evolved amongst herpesviruses to modulate the antigen presentation pathway. Despite related viruses targeting the same points in the antigen presenting pathway, the molecular properties of the viral proteins (which often have other functions besides immune-evasion), and the precise molecular mechanisms by which they act, suggest a bewildering complexity of independent evolutionary events driving the development of each herpesvirus. Even when a subgroup of viruses has acquired a second function in a viral protein with an already essential and conserved function in all herpesviruses, as is the case with the acquired shutoff function by DNases of γ-herpesviruses, it is possible that different molecular mechanisms evolved to effect this additional immune-evasion function. Finally, it should be noted that the multiple immune-evasion mechanisms of a virus do not necessarily afford absolute protection. The evasion mechanisms should be considered as strategies to dampen the efficiency of very potent immune T cell responses to lytic cycle gene products, rather than to completely evade them. This subtle modulation of immune responses plays an important role in enabling herpesviruses to persist as a largely asymptomatic infection.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="bib1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Callan</surname>
              <given-names>M.F.</given-names>
            </name>
            <name>
              <surname>Steven</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Krausa</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Moss</surname>
              <given-names>P.A.</given-names>
            </name>
            <name>
              <surname>Gillespie</surname>
              <given-names>G.M.</given-names>
            </name>
            <name>
              <surname>Bell</surname>
              <given-names>J.I.</given-names>
            </name>
            <name>
              <surname>Rickinson</surname>
              <given-names>A.B.</given-names>
            </name>
            <name>
              <surname>McMichael</surname>
              <given-names>A.J.</given-names>
            </name>
          </person-group>
          <article-title>Large clonal expansions of CD8+ T cells in acute infectious mononucleosis</article-title>
          <source>Nat. Med.</source>
          <volume>2</volume>
          <year>1996</year>
          <fpage>906</fpage>
          <lpage>911</lpage>
          <pub-id pub-id-type="pmid">8705861</pub-id>
        </element-citation>
      </ref>
      <ref id="bib2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haque</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Wilkie</surname>
              <given-names>G.M.</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Amlot</surname>
              <given-names>P.L.</given-names>
            </name>
            <name>
              <surname>Murad</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Iley</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Dombagoda</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Britton</surname>
              <given-names>K.M.</given-names>
            </name>
            <name>
              <surname>Swerdlow</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Crawford</surname>
              <given-names>D.H.</given-names>
            </name>
          </person-group>
          <article-title>Treatment of Epstein–Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells</article-title>
          <source>Lancet</source>
          <volume>360</volume>
          <year>2002</year>
          <fpage>436</fpage>
          <lpage>442</lpage>
          <pub-id pub-id-type="pmid">12241714</pub-id>
        </element-citation>
      </ref>
      <ref id="bib3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rooney</surname>
              <given-names>C.M.</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Ng</surname>
              <given-names>C.Y.</given-names>
            </name>
            <name>
              <surname>Loftin</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Krance</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Brenner</surname>
              <given-names>M.K.</given-names>
            </name>
            <name>
              <surname>Heslop</surname>
              <given-names>H.E.</given-names>
            </name>
          </person-group>
          <article-title>Use of gene-modified virus-specific T lymphocytes to control Epstein–Barr-virus-related lymphoproliferation</article-title>
          <source>Lancet</source>
          <volume>345</volume>
          <year>1995</year>
          <fpage>9</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="pmid">7799740</pub-id>
        </element-citation>
      </ref>
      <ref id="bib4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rowe</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Kelly</surname>
              <given-names>G.L.</given-names>
            </name>
            <name>
              <surname>Bell</surname>
              <given-names>A.I.</given-names>
            </name>
            <name>
              <surname>Rickinson</surname>
              <given-names>A.B.</given-names>
            </name>
          </person-group>
          <article-title>Burkitt's lymphoma: the Rosetta stone deciphering Epstein–Barr virus biology</article-title>
          <source>Semin. Cancer Biol.</source>
          <volume>19</volume>
          <year>2009</year>
          <fpage>377</fpage>
          <lpage>388</lpage>
          <pub-id pub-id-type="pmid">19619657</pub-id>
        </element-citation>
      </ref>
      <ref id="bib5">
        <label>5</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Rickinson</surname>
              <given-names>A.B.</given-names>
            </name>
            <name>
              <surname>Kieff</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <chapter-title>Epstein–Barr virus</chapter-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Knipe</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Howley</surname>
              <given-names>P.M.</given-names>
            </name>
          </person-group>
          <source>Fields Virology</source>
          <year>2007</year>
          <publisher-name>Walters Kluwer/Lippincott, Williams &amp; Wilkins</publisher-name>
          <publisher-loc>Philadelphia</publisher-loc>
          <fpage>2655</fpage>
          <lpage>2700</lpage>
        </element-citation>
      </ref>
      <ref id="bib6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thorley-Lawson</surname>
              <given-names>D.A.</given-names>
            </name>
          </person-group>
          <article-title>Epstein–Barr virus: exploiting the immune system</article-title>
          <source>Nat. Rev. Immunol.</source>
          <volume>1</volume>
          <year>2001</year>
          <fpage>75</fpage>
          <lpage>82</lpage>
          <pub-id pub-id-type="pmid">11905817</pub-id>
        </element-citation>
      </ref>
      <ref id="bib7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rowe</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Khanna</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Jacob</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Argaet</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Kelly</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Powis</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Belich</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Croom-Carter</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Burrows</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Trowsdale</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Moss</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Rickinson</surname>
              <given-names>A.B.</given-names>
            </name>
          </person-group>
          <article-title>Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein Barr virus latent membrane protein-1: coordinate upregulation of peptide transporters and HLA class I antigen expression</article-title>
          <source>Eur. J. Immunol.</source>
          <volume>25</volume>
          <year>1995</year>
          <fpage>1374</fpage>
          <lpage>1384</lpage>
          <pub-id pub-id-type="pmid">7774641</pub-id>
        </element-citation>
      </ref>
      <ref id="bib8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hislop</surname>
              <given-names>A.D.</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>G.S.</given-names>
            </name>
            <name>
              <surname>Sauce</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Rickinson</surname>
              <given-names>A.B.</given-names>
            </name>
          </person-group>
          <article-title>Cellular responses to viral infection in humans: lessons from Epstein–Barr virus</article-title>
          <source>Annu. Rev. Immunol.</source>
          <volume>25</volume>
          <year>2007</year>
          <fpage>587</fpage>
          <lpage>617</lpage>
          <pub-id pub-id-type="pmid">17378764</pub-id>
        </element-citation>
      </ref>
      <ref id="bib9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Niedobitek</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Agathanggelou</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Herbst</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Whitehead</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Wright</surname>
              <given-names>D.H.</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>L.S.</given-names>
            </name>
          </person-group>
          <article-title>Epstein–Barr virus (EBV) infection in infectious mononucleosis: virus latency, replication and phenotype of EBV-infected cells</article-title>
          <source>J. Pathol.</source>
          <volume>182</volume>
          <year>1997</year>
          <fpage>151</fpage>
          <lpage>159</lpage>
          <pub-id pub-id-type="pmid">9274524</pub-id>
        </element-citation>
      </ref>
      <ref id="bib10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yao</surname>
              <given-names>Q.Y.</given-names>
            </name>
            <name>
              <surname>Rowe</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>L.S.</given-names>
            </name>
            <name>
              <surname>Rickinson</surname>
              <given-names>A.B.</given-names>
            </name>
          </person-group>
          <article-title>The Epstein–Barr virus carrier state: dominance of a single growth-transforming isolate in the blood and in the oropharynx of healthy virus carriers</article-title>
          <source>J. Gen. Virol.</source>
          <volume>72</volume>
          <year>1991</year>
          <fpage>1579</fpage>
          <lpage>1590</lpage>
          <pub-id pub-id-type="pmid">1649896</pub-id>
        </element-citation>
      </ref>
      <ref id="bib11">
        <label>11</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Thorley-Lawson</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <chapter-title>EBV persistence and latent infection in vivo</chapter-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Robertson</surname>
              <given-names>E.S.</given-names>
            </name>
          </person-group>
          <source>Epstein–Barr Virus</source>
          <year>2005</year>
          <publisher-name>Caister Academic Press</publisher-name>
          <publisher-loc>Norfolk</publisher-loc>
          <fpage>309</fpage>
          <lpage>357</lpage>
        </element-citation>
      </ref>
      <ref id="bib12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Babcock</surname>
              <given-names>G.J.</given-names>
            </name>
            <name>
              <surname>Decker</surname>
              <given-names>L.L.</given-names>
            </name>
            <name>
              <surname>Freeman</surname>
              <given-names>R.B.</given-names>
            </name>
            <name>
              <surname>Thorley-Lawson</surname>
              <given-names>D.A.</given-names>
            </name>
          </person-group>
          <article-title>Epstein–Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients</article-title>
          <source>J. Exp. Med.</source>
          <volume>190</volume>
          <year>1999</year>
          <fpage>567</fpage>
          <lpage>576</lpage>
          <pub-id pub-id-type="pmid">10449527</pub-id>
        </element-citation>
      </ref>
      <ref id="bib13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shannon-Lowe</surname>
              <given-names>C.D.</given-names>
            </name>
            <name>
              <surname>Neuhierl</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Baldwin</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Rickinson</surname>
              <given-names>A.B.</given-names>
            </name>
            <name>
              <surname>Delecluse</surname>
              <given-names>H.J.</given-names>
            </name>
          </person-group>
          <article-title>Resting B cells as a transfer vehicle for Epstein–Barr virus infection of epithelial cells</article-title>
          <source>Proc. Natl. Acad. Sci. U.S.A.</source>
          <volume>103</volume>
          <year>2006</year>
          <fpage>7065</fpage>
          <lpage>7070</lpage>
          <pub-id pub-id-type="pmid">16606841</pub-id>
        </element-citation>
      </ref>
      <ref id="bib14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Young</surname>
              <given-names>L.S.</given-names>
            </name>
            <name>
              <surname>Lau</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Rowe</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Niedobitek</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Packham</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Shanaham</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Rowe</surname>
              <given-names>D.T.</given-names>
            </name>
            <name>
              <surname>Greenspan</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Greenspan</surname>
              <given-names>J.S.</given-names>
            </name>
            <name>
              <surname>Rickinson</surname>
              <given-names>A.B.</given-names>
            </name>
            <name>
              <surname>Farrell</surname>
              <given-names>P.J.</given-names>
            </name>
          </person-group>
          <article-title>Differentiation-associated expression of the Epstein–Barr virus BZLF1 transactivator protein in oral “hairy” leukoplakia</article-title>
          <source>J. Virol.</source>
          <volume>65</volume>
          <year>1991</year>
          <fpage>2868</fpage>
          <lpage>2874</lpage>
          <pub-id pub-id-type="pmid">1851858</pub-id>
        </element-citation>
      </ref>
      <ref id="bib15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Niedobitek</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Agathanggelou</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Steven</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>L.S.</given-names>
            </name>
          </person-group>
          <article-title>Epstein–Barr virus (EBV) in infectious mononucleosis: detection of the virus in tonsillar B lymphocytes but not in desquamated oropharyngeal epithelial cells</article-title>
          <source>Mol. Pathol.</source>
          <volume>53</volume>
          <year>2000</year>
          <fpage>37</fpage>
          <lpage>42</lpage>
          <pub-id pub-id-type="pmid">10884920</pub-id>
        </element-citation>
      </ref>
      <ref id="bib16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hudnall</surname>
              <given-names>S.D.</given-names>
            </name>
            <name>
              <surname>Ge</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Wei</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>N.P.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>H.Q.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Distribution and phenotype of Epstein–Barr virus-infected cells in human pharyngeal tonsils</article-title>
          <source>Mod. Pathol.</source>
          <volume>18</volume>
          <year>2005</year>
          <fpage>519</fpage>
          <lpage>527</lpage>
          <pub-id pub-id-type="pmid">15696119</pub-id>
        </element-citation>
      </ref>
      <ref id="bib17">
        <label>17</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Kieff</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Rickinson</surname>
              <given-names>A.B.</given-names>
            </name>
          </person-group>
          <chapter-title>Epstein–Barr virus and its replication</chapter-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Knipe</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Howley</surname>
              <given-names>P.M.</given-names>
            </name>
          </person-group>
          <source>Fields Virology</source>
          <year>2007</year>
          <publisher-name>Walters Kluwer/Lippincott, Williams &amp; Wilkins</publisher-name>
          <publisher-loc>Philadelphia</publisher-loc>
          <fpage>2603</fpage>
          <lpage>2654</lpage>
        </element-citation>
      </ref>
      <ref id="bib18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Croft</surname>
              <given-names>N.P.</given-names>
            </name>
            <name>
              <surname>Shannon-Lowe</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Bell</surname>
              <given-names>A.I.</given-names>
            </name>
            <name>
              <surname>Horst</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Kremmer</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Ressing</surname>
              <given-names>M.E.</given-names>
            </name>
            <name>
              <surname>Wiertz</surname>
              <given-names>E.J.</given-names>
            </name>
            <name>
              <surname>Middeldorp</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Rowe</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Rickinson</surname>
              <given-names>A.B.</given-names>
            </name>
            <name>
              <surname>Hislop</surname>
              <given-names>A.D.</given-names>
            </name>
          </person-group>
          <article-title>Stage-specific inhibition of MHC class I presentation by the Epstein–Barr virus BNLF2a protein during virus lytic cycle</article-title>
          <source>PLoS Pathog.</source>
          <volume>5</volume>
          <year>2009</year>
          <fpage>e1000490</fpage>
          <pub-id pub-id-type="pmid">19557156</pub-id>
        </element-citation>
      </ref>
      <ref id="bib19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ressing</surname>
              <given-names>M.E.</given-names>
            </name>
            <name>
              <surname>Keating</surname>
              <given-names>S.E.</given-names>
            </name>
            <name>
              <surname>van Leeuwen</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Koppers-Lalic</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Pappworth</surname>
              <given-names>I.Y.</given-names>
            </name>
            <name>
              <surname>Wiertz</surname>
              <given-names>E.J.H.J.</given-names>
            </name>
            <name>
              <surname>Rowe</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Impaired transporter associated with antigen processing-dependent peptide transport during productive EBV infection</article-title>
          <source>J. Immunol.</source>
          <volume>174</volume>
          <year>2005</year>
          <fpage>6829</fpage>
          <lpage>6838</lpage>
          <pub-id pub-id-type="pmid">15905524</pub-id>
        </element-citation>
      </ref>
      <ref id="bib20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bhaduri-McIntosh</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Landry</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Nikiforow</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Rotenberg</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>El-Guindy</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Serum IgA antibodies to Epstein–Barr virus (EBV) early lytic antigens are present in primary EBV infection</article-title>
          <source>J. Infect. Dis.</source>
          <volume>195</volume>
          <year>2007</year>
          <fpage>483</fpage>
          <lpage>492</lpage>
          <pub-id pub-id-type="pmid">17230407</pub-id>
        </element-citation>
      </ref>
      <ref id="bib21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pudney</surname>
              <given-names>V.A.</given-names>
            </name>
            <name>
              <surname>Leese</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Rickinson</surname>
              <given-names>A.B.</given-names>
            </name>
            <name>
              <surname>Hislop</surname>
              <given-names>A.D.</given-names>
            </name>
          </person-group>
          <article-title>CD8+ immunodominance among Epstein–Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells</article-title>
          <source>J. Exp. Med.</source>
          <volume>201</volume>
          <year>2005</year>
          <fpage>349</fpage>
          <lpage>360</lpage>
          <pub-id pub-id-type="pmid">15684323</pub-id>
        </element-citation>
      </ref>
      <ref id="bib22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zeidler</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Eissner</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Meissner</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Uebel</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Tampe</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Lazis</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Hammerschmidt</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <article-title>Downregulation of TAP1 in B lymphocytes by cellular and Epstein–Barr virus-encoded interleukin-10</article-title>
          <source>Blood</source>
          <volume>90</volume>
          <year>1997</year>
          <fpage>2390</fpage>
          <lpage>2397</lpage>
          <pub-id pub-id-type="pmid">9310490</pub-id>
        </element-citation>
      </ref>
      <ref id="bib23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stewart</surname>
              <given-names>J.P.</given-names>
            </name>
            <name>
              <surname>Rooney</surname>
              <given-names>C.M.</given-names>
            </name>
          </person-group>
          <article-title>The interleukin-10 homolog encoded by Epstein–Barr virus enhances the reactivation of virus-specific cytotoxic T cell and HLA-unrestricted killer cell responses</article-title>
          <source>Virology</source>
          <volume>191</volume>
          <year>1992</year>
          <fpage>773</fpage>
          <lpage>782</lpage>
          <pub-id pub-id-type="pmid">1333123</pub-id>
        </element-citation>
      </ref>
      <ref id="bib24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Levitskaya</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Sharipo</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Leonchiks</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Ciechanover</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Masucci</surname>
              <given-names>M.G.</given-names>
            </name>
          </person-group>
          <article-title>Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein–Barr virus nuclear antigen 1</article-title>
          <source>Proc. Natl. Acad. Sci. U.S.A.</source>
          <volume>94</volume>
          <year>1997</year>
          <fpage>12616</fpage>
          <lpage>12621</lpage>
          <pub-id pub-id-type="pmid">9356498</pub-id>
        </element-citation>
      </ref>
      <ref id="bib25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Qian</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Shi</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Guo</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein–Barr virus reactivation</article-title>
          <source>J. Immunol.</source>
          <volume>182</volume>
          <year>2009</year>
          <fpage>1799</fpage>
          <lpage>1809</lpage>
          <pub-id pub-id-type="pmid">19201831</pub-id>
        </element-citation>
      </ref>
      <ref id="bib26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rowe</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Glaunsinger</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>van Leeuwen</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Zuo</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Sweetman</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Ganem</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Middeldorp</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Wiertz</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Ressing</surname>
              <given-names>M.E.</given-names>
            </name>
          </person-group>
          <article-title>Host shut off during productive Epstein–Barr virus infection is mediated by BGLF5 and may contribute to immune evasion</article-title>
          <source>Proc. Natl. Acad. Sci. U.S.A.</source>
          <volume>104</volume>
          <year>2007</year>
          <fpage>3366</fpage>
          <lpage>3371</lpage>
          <pub-id pub-id-type="pmid">17360652</pub-id>
        </element-citation>
      </ref>
      <ref id="bib27">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ressing</surname>
              <given-names>M.E.</given-names>
            </name>
            <name>
              <surname>van Leeuwen</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Verreck</surname>
              <given-names>F.A.</given-names>
            </name>
            <name>
              <surname>Gomez</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Heemskerk</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Toebes</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Mullen</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Jardetzky</surname>
              <given-names>T.S.</given-names>
            </name>
            <name>
              <surname>Longnecker</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Schilham</surname>
              <given-names>M.W.</given-names>
            </name>
            <name>
              <surname>Ottenhoff</surname>
              <given-names>T.H.</given-names>
            </name>
            <name>
              <surname>Neefjes</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Schumacher</surname>
              <given-names>T.N.</given-names>
            </name>
            <name>
              <surname>Hutt-Fletcher</surname>
              <given-names>L.M.</given-names>
            </name>
            <name>
              <surname>Wiertz</surname>
              <given-names>E.J.</given-names>
            </name>
          </person-group>
          <article-title>Interference with T cell receptor-HLA-DR interactions by Epstein–Barr virus gp42 results in reduced T helper cell recognition</article-title>
          <source>Proc. Natl. Acad. Sci. U.S.A.</source>
          <volume>100</volume>
          <year>2003</year>
          <fpage>11583</fpage>
          <lpage>11588</lpage>
          <pub-id pub-id-type="pmid">14504389</pub-id>
        </element-citation>
      </ref>
      <ref id="bib28">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ressing</surname>
              <given-names>M.E.</given-names>
            </name>
            <name>
              <surname>van Leeuwen</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Verreck</surname>
              <given-names>F.A.</given-names>
            </name>
            <name>
              <surname>Keating</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Gomez</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Franken</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Ottenhoff</surname>
              <given-names>T.H.M.</given-names>
            </name>
            <name>
              <surname>Spriggs</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Schumacher</surname>
              <given-names>T.N.</given-names>
            </name>
            <name>
              <surname>Hutt-Fletcher</surname>
              <given-names>L.M.</given-names>
            </name>
            <name>
              <surname>Rowe</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Wiertz</surname>
              <given-names>E.J.H.J.</given-names>
            </name>
          </person-group>
          <article-title>Epstein–Barr virus gp-42 is posttranslationally modified to produce soluble s-gp42 that mediates HLA class II immune evasion</article-title>
          <source>J. Virol.</source>
          <volume>79</volume>
          <year>2005</year>
          <fpage>841</fpage>
          <lpage>852</lpage>
          <pub-id pub-id-type="pmid">15613312</pub-id>
        </element-citation>
      </ref>
      <ref id="bib29">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morrison</surname>
              <given-names>T.E.</given-names>
            </name>
            <name>
              <surname>Mauser</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Ting</surname>
              <given-names>J.P.</given-names>
            </name>
            <name>
              <surname>Kenney</surname>
              <given-names>S.C.</given-names>
            </name>
          </person-group>
          <article-title>Inhibition of IFN-gamma signaling by an Epstein–Barr virus immediate-early protein</article-title>
          <source>Immunity</source>
          <volume>15</volume>
          <year>2001</year>
          <fpage>787</fpage>
          <lpage>799</lpage>
          <pub-id pub-id-type="pmid">11728340</pub-id>
        </element-citation>
      </ref>
      <ref id="bib30">
        <label>30</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Miller-Kittrell</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Sparer</surname>
              <given-names>T.E.</given-names>
            </name>
          </person-group>
          <article-title>Feeling manipulated: cytomegalovirus immune manipulation</article-title>
          <source>Virol. J.</source>
          <volume>6</volume>
          <year>2009</year>
          <fpage>4</fpage>
          <pub-id pub-id-type="pmid">19134204</pub-id>
        </element-citation>
      </ref>
      <ref id="bib31">
        <label>31</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hansen</surname>
              <given-names>T.H.</given-names>
            </name>
            <name>
              <surname>Bouvier</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>MHC class I antigen presentation: learning from viral evasion strategies</article-title>
          <source>Nat. Rev. Immunol.</source>
          <volume>9</volume>
          <year>2009</year>
          <fpage>503</fpage>
          <lpage>513</lpage>
          <pub-id pub-id-type="pmid">19498380</pub-id>
        </element-citation>
      </ref>
      <ref id="bib32">
        <label>32</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Keating</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Prince</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Rowe</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>The lytic cycle of Epstein–Barr virus is associated with decreased expression of cell surface MHC class I and class II</article-title>
          <source>J. Virol.</source>
          <volume>76</volume>
          <year>2002</year>
          <fpage>8179</fpage>
          <lpage>8188</lpage>
          <pub-id pub-id-type="pmid">12134023</pub-id>
        </element-citation>
      </ref>
      <ref id="bib33">
        <label>33</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Guerreiro-Cacais</surname>
              <given-names>A.O.</given-names>
            </name>
            <name>
              <surname>Uzunel</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Levitskaya</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Levitsky</surname>
              <given-names>V.</given-names>
            </name>
          </person-group>
          <article-title>Inhibition of heavy chain and {beta}2-microglobulin synthesis as a mechanism of major histocompatibility complex class I downregulation during Epstein–Barr virus replication</article-title>
          <source>J. Virol.</source>
          <volume>81</volume>
          <year>2007</year>
          <fpage>1390</fpage>
          <lpage>1400</lpage>
          <pub-id pub-id-type="pmid">17108039</pub-id>
        </element-citation>
      </ref>
      <ref id="bib34">
        <label>34</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hislop</surname>
              <given-names>A.D.</given-names>
            </name>
            <name>
              <surname>Ressing</surname>
              <given-names>M.E.</given-names>
            </name>
            <name>
              <surname>van Leeuwen</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Pudney</surname>
              <given-names>V.A.</given-names>
            </name>
            <name>
              <surname>Horst</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Koppers-Lalic</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Croft</surname>
              <given-names>N.P.</given-names>
            </name>
            <name>
              <surname>Neefjes</surname>
              <given-names>J.J.</given-names>
            </name>
            <name>
              <surname>Rickinson</surname>
              <given-names>A.B.</given-names>
            </name>
            <name>
              <surname>Wiertz</surname>
              <given-names>E.J.</given-names>
            </name>
          </person-group>
          <article-title>A CD8<sup>+</sup> T cell immune evasion protein specific to Epstein–Barr virus and its close relatives in Old World primates</article-title>
          <source>J. Exp. Med.</source>
          <volume>204</volume>
          <year>2007</year>
          <fpage>1863</fpage>
          <lpage>1873</lpage>
          <pub-id pub-id-type="pmid">17620360</pub-id>
        </element-citation>
      </ref>
      <ref id="bib35">
        <label>35</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Strockbine</surname>
              <given-names>L.D.</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>J.I.</given-names>
            </name>
            <name>
              <surname>Farrah</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Lyman</surname>
              <given-names>S.D.</given-names>
            </name>
            <name>
              <surname>Wagener</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>DuBose</surname>
              <given-names>R.F.</given-names>
            </name>
            <name>
              <surname>Armitage</surname>
              <given-names>R.J.</given-names>
            </name>
            <name>
              <surname>Spriggs</surname>
              <given-names>M.K.</given-names>
            </name>
          </person-group>
          <article-title>The Epstein–Barr virus BARF1 gene encodes a novel, soluble colony-stimulating factor-1 receptor</article-title>
          <source>J. Virol.</source>
          <volume>72</volume>
          <year>1998</year>
          <fpage>4015</fpage>
          <lpage>4021</lpage>
          <pub-id pub-id-type="pmid">9557689</pub-id>
        </element-citation>
      </ref>
      <ref id="bib36">
        <label>36</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Horst</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>van Leeuwen</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Croft</surname>
              <given-names>N.P.</given-names>
            </name>
            <name>
              <surname>Garstka</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Hislop</surname>
              <given-names>A.D.</given-names>
            </name>
            <name>
              <surname>Kremmer</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Rickinson</surname>
              <given-names>A.B.</given-names>
            </name>
            <name>
              <surname>Wiertz</surname>
              <given-names>E.J.</given-names>
            </name>
            <name>
              <surname>Ressing</surname>
              <given-names>M.E.</given-names>
            </name>
          </person-group>
          <article-title>Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation</article-title>
          <source>J. Immunol.</source>
          <volume>182</volume>
          <year>2009</year>
          <fpage>2313</fpage>
          <lpage>2324</lpage>
          <pub-id pub-id-type="pmid">19201886</pub-id>
        </element-citation>
      </ref>
      <ref id="bib37">
        <label>37</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kyritsis</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Gorbulev</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Hutschenreiter</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Pawlitschko</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Abele</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Tampe</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Molecular mechanism and structural aspects of transporter associated with antigen processing inhibition by the cytomegalovirus protein US6</article-title>
          <source>J. Biol. Chem.</source>
          <volume>276</volume>
          <year>2001</year>
          <fpage>48031</fpage>
          <lpage>48039</lpage>
          <pub-id pub-id-type="pmid">11606590</pub-id>
        </element-citation>
      </ref>
      <ref id="bib38">
        <label>38</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ahn</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Meyer</surname>
              <given-names>T.H.</given-names>
            </name>
            <name>
              <surname>Uebel</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Sempe</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Djaballah</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Peterson</surname>
              <given-names>P.A.</given-names>
            </name>
            <name>
              <surname>Fruh</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Tampe</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47</article-title>
          <source>EMBO J.</source>
          <volume>15</volume>
          <year>1996</year>
          <fpage>3247</fpage>
          <lpage>3255</lpage>
          <pub-id pub-id-type="pmid">8670825</pub-id>
        </element-citation>
      </ref>
      <ref id="bib39">
        <label>39</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tomazin</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Hill</surname>
              <given-names>A.B.</given-names>
            </name>
            <name>
              <surname>Jugovic</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>York</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>van Endert</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Ploegh</surname>
              <given-names>H.L.</given-names>
            </name>
            <name>
              <surname>Andrews</surname>
              <given-names>D.W.</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>D.C.</given-names>
            </name>
          </person-group>
          <article-title>Stable binding of the herpes simplex virus ICP47 protein to the peptide binding site of TAP</article-title>
          <source>EMBO J.</source>
          <volume>15</volume>
          <year>1996</year>
          <fpage>3256</fpage>
          <lpage>3266</lpage>
          <pub-id pub-id-type="pmid">8670826</pub-id>
        </element-citation>
      </ref>
      <ref id="bib40">
        <label>40</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koppers-Lalic</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Reits</surname>
              <given-names>E.A.</given-names>
            </name>
            <name>
              <surname>Ressing</surname>
              <given-names>M.E.</given-names>
            </name>
            <name>
              <surname>Lipinska</surname>
              <given-names>A.D.</given-names>
            </name>
            <name>
              <surname>Abele</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Koch</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Rezende</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Admiraal</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>van Leeuwen</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Bienkowska-Szewczyk</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Mettenleiter</surname>
              <given-names>T.C.</given-names>
            </name>
            <name>
              <surname>Rijsewijk</surname>
              <given-names>F.A.</given-names>
            </name>
            <name>
              <surname>Tampe</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Neefjes</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Wiertz</surname>
              <given-names>E.J.</given-names>
            </name>
          </person-group>
          <article-title>Varicelloviruses avoid T cell recognition by targeting TAP for degradation</article-title>
          <source>Proc. Natl. Acad. Sci. U.S.A.</source>
          <volume>102</volume>
          <year>2005</year>
          <fpage>5144</fpage>
          <lpage>5149</lpage>
          <pub-id pub-id-type="pmid">15793001</pub-id>
        </element-citation>
      </ref>
      <ref id="bib41">
        <label>41</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lipinska</surname>
              <given-names>A.D.</given-names>
            </name>
            <name>
              <surname>Koppers-Lalic</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Rychlowski</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Admiraal</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Rijsewijk</surname>
              <given-names>F.A.</given-names>
            </name>
            <name>
              <surname>Bienkowska-Szewczyk</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Wiertz</surname>
              <given-names>E.J.</given-names>
            </name>
          </person-group>
          <article-title>Bovine herpesvirus 1 UL49.5 protein inhibits the transporter associated with antigen processing despite complex formation with glycoprotein M</article-title>
          <source>J. Virol.</source>
          <volume>80</volume>
          <year>2006</year>
          <fpage>5822</fpage>
          <lpage>5832</lpage>
          <pub-id pub-id-type="pmid">16731921</pub-id>
        </element-citation>
      </ref>
      <ref id="bib42">
        <label>42</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baylis</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Purifoy</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Littler</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>The characterization of the EBV alkaline deoxyribonuclease cloned and expressed in E. coli</article-title>
          <source>Nucleic Acids Res.</source>
          <volume>17</volume>
          <year>1989</year>
          <fpage>7609</fpage>
          <lpage>7622</lpage>
          <pub-id pub-id-type="pmid">2552412</pub-id>
        </element-citation>
      </ref>
      <ref id="bib43">
        <label>43</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martinez</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Sarisky</surname>
              <given-names>R.T.</given-names>
            </name>
            <name>
              <surname>Weber</surname>
              <given-names>P.C.</given-names>
            </name>
            <name>
              <surname>Weller</surname>
              <given-names>S.K.</given-names>
            </name>
          </person-group>
          <article-title>Herpes simplex virus type 1 alkaline nuclease is required for efficient processing of viral DNA replication intermediates</article-title>
          <source>J. Virol.</source>
          <volume>70</volume>
          <year>1996</year>
          <fpage>2075</fpage>
          <lpage>2085</lpage>
          <pub-id pub-id-type="pmid">8642627</pub-id>
        </element-citation>
      </ref>
      <ref id="bib44">
        <label>44</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shao</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Rapp</surname>
              <given-names>L.M.</given-names>
            </name>
            <name>
              <surname>Weller</surname>
              <given-names>S.K.</given-names>
            </name>
          </person-group>
          <article-title>Herpes simplex virus 1 alkaline nuclease is required for efficient egress of capsids from the nucleus</article-title>
          <source>Virology</source>
          <volume>196</volume>
          <year>1993</year>
          <fpage>146</fpage>
          <lpage>162</lpage>
          <pub-id pub-id-type="pmid">8395111</pub-id>
        </element-citation>
      </ref>
      <ref id="bib45">
        <label>45</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Feederle</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Bannert</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Lips</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Muller-Lantzsch</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Delecluse</surname>
              <given-names>H.J.</given-names>
            </name>
          </person-group>
          <article-title>The Epstein–Barr virus alkaline exonuclease BGLF5 serves pleiotropic functions in virus replication</article-title>
          <source>J. Virol.</source>
          <volume>83</volume>
          <year>2009</year>
          <fpage>4952</fpage>
          <lpage>4962</lpage>
          <pub-id pub-id-type="pmid">19264771</pub-id>
        </element-citation>
      </ref>
      <ref id="bib46">
        <label>46</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Goldstein</surname>
              <given-names>J.N.</given-names>
            </name>
            <name>
              <surname>Weller</surname>
              <given-names>S.K.</given-names>
            </name>
          </person-group>
          <article-title>The exonuclease activity of HSV-1 UL12 is required for in vivo function</article-title>
          <source>Virology</source>
          <volume>244</volume>
          <year>1998</year>
          <fpage>442</fpage>
          <lpage>457</lpage>
          <pub-id pub-id-type="pmid">9601512</pub-id>
        </element-citation>
      </ref>
      <ref id="bib47">
        <label>47</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bujnicki</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Rychlewski</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>The herpesvirus alkaline exonuclease belongs to the restriction endonuclease PD-(D/E)XK superfamily: insight from molecular modeling and phylogenetic analysis</article-title>
          <source>Virus Genes</source>
          <volume>22</volume>
          <year>2001</year>
          <fpage>219</fpage>
          <lpage>230</lpage>
          <pub-id pub-id-type="pmid">11324759</pub-id>
        </element-citation>
      </ref>
      <ref id="bib48">
        <label>48</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>M.T.</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>H.P.</given-names>
            </name>
            <name>
              <surname>Hsu</surname>
              <given-names>T.Y.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>J.Y.</given-names>
            </name>
          </person-group>
          <article-title>Site-directed mutagenesis in a conserved motif of Epstein–Barr virus DNase that is homologous to the catalytic centre of type II restriction endonucleases</article-title>
          <source>J. Gen. Virol.</source>
          <volume>84</volume>
          <year>2003</year>
          <fpage>677</fpage>
          <lpage>686</lpage>
          <pub-id pub-id-type="pmid">12604820</pub-id>
        </element-citation>
      </ref>
      <ref id="bib49">
        <label>49</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Buisson</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Geoui</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Flot</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Tarbouriech</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Ressing</surname>
              <given-names>M.E.</given-names>
            </name>
            <name>
              <surname>Wiertz</surname>
              <given-names>E.J.</given-names>
            </name>
            <name>
              <surname>Burmeister</surname>
              <given-names>W.P.</given-names>
            </name>
          </person-group>
          <article-title>A bridge crosses the active-site canyon of the Epstein–Barr virus nuclease with DNase and RNase activities</article-title>
          <source>J. Mol. Biol.</source>
          <volume>391</volume>
          <year>2009</year>
          <fpage>717</fpage>
          <lpage>728</lpage>
          <pub-id pub-id-type="pmid">19538972</pub-id>
        </element-citation>
      </ref>
      <ref id="bib50">
        <label>50</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Glaunsinger</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Ganem</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Lytic KSHV infection inhibits host gene expression by accelerating global mRNA turnover</article-title>
          <source>Mol. Cells</source>
          <volume>13</volume>
          <year>2004</year>
          <fpage>713</fpage>
          <lpage>723</lpage>
        </element-citation>
      </ref>
      <ref id="bib51">
        <label>51</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zuo</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>van Leeuwen</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Middeldorp</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Wiertz</surname>
              <given-names>E.J.</given-names>
            </name>
            <name>
              <surname>Ressing</surname>
              <given-names>M.E.</given-names>
            </name>
            <name>
              <surname>Rowe</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>The DNase of gammaherpesviruses impairs recognition by virus-specific CD8+ T cells through an additional host shutoff function</article-title>
          <source>J. Virol.</source>
          <volume>82</volume>
          <year>2008</year>
          <fpage>2385</fpage>
          <lpage>2393</lpage>
          <pub-id pub-id-type="pmid">18094150</pub-id>
        </element-citation>
      </ref>
      <ref id="bib52">
        <label>52</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Glaunsinger</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Chavez</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Ganem</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>The exonuclease and host shutoff functions of the SOX protein of Kaposi's Sarcoma-associated herpesvirus are genetically separable</article-title>
          <source>J. Virol.</source>
          <volume>79</volume>
          <year>2005</year>
          <fpage>7396</fpage>
          <lpage>7401</lpage>
          <pub-id pub-id-type="pmid">15919895</pub-id>
        </element-citation>
      </ref>
      <ref id="bib53">
        <label>53</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Covarrubias</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Richner</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Clyde</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>Y.J.</given-names>
            </name>
            <name>
              <surname>Glaunsinger</surname>
              <given-names>B.A.</given-names>
            </name>
          </person-group>
          <article-title>Host shutoff is a conserved phenotype of gammaherpesvirus infection and is orchestrated exclusively from the cytoplasm</article-title>
          <source>J. Virol.</source>
          <volume>83</volume>
          <year>2009</year>
          <fpage>9554</fpage>
          <lpage>9566</lpage>
          <pub-id pub-id-type="pmid">19587049</pub-id>
        </element-citation>
      </ref>
      <ref id="bib54">
        <label>54</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smiley</surname>
              <given-names>J.R.</given-names>
            </name>
          </person-group>
          <article-title>Herpes simplex virus virion host shutoff protein: immune evasion mediated by a viral RNase?</article-title>
          <source>J. Virol.</source>
          <volume>78</volume>
          <year>2004</year>
          <fpage>1063</fpage>
          <lpage>1068</lpage>
          <pub-id pub-id-type="pmid">14722261</pub-id>
        </element-citation>
      </ref>
      <ref id="bib55">
        <label>55</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>Y.J.</given-names>
            </name>
            <name>
              <surname>Glaunsinger</surname>
              <given-names>B.A.</given-names>
            </name>
          </person-group>
          <article-title>Aberrant herpesvirus-induced polyadenylation correlates with cellular messenger RNA destruction</article-title>
          <source>PLoS Biol.</source>
          <volume>7</volume>
          <year>2009</year>
          <fpage>e1000107</fpage>
          <pub-id pub-id-type="pmid">19468299</pub-id>
        </element-citation>
      </ref>
      <ref id="bib56">
        <label>56</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dahlroth</surname>
              <given-names>S.L.</given-names>
            </name>
            <name>
              <surname>Gurmu</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Haas</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Erlandsen</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Nordlund</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Crystal structure of the shutoff and exonuclease protein from the oncogenic Kaposi's sarcoma-associated herpesvirus</article-title>
          <source>FEBS J.</source>
          <year>2009</year>
        </element-citation>
      </ref>
      <ref id="bib57">
        <label>57</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zuo</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Currin</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Griffin</surname>
              <given-names>B.D.</given-names>
            </name>
            <name>
              <surname>Shannon-Lowe</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>W.A.</given-names>
            </name>
            <name>
              <surname>Ressing</surname>
              <given-names>M.E.</given-names>
            </name>
            <name>
              <surname>Wiertz</surname>
              <given-names>E.J.</given-names>
            </name>
            <name>
              <surname>Rowe</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>The Epstein–Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation</article-title>
          <source>PLoS Pathog.</source>
          <volume>5</volume>
          <year>2009</year>
          <fpage>e1000255</fpage>
          <pub-id pub-id-type="pmid">19119421</pub-id>
        </element-citation>
      </ref>
      <ref id="bib58">
        <label>58</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Beisser</surname>
              <given-names>P.S.</given-names>
            </name>
            <name>
              <surname>Verzijl</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Gruijthuijsen</surname>
              <given-names>Y.K.</given-names>
            </name>
            <name>
              <surname>Beuken</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Smit</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Leurs</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Bruggeman</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Vink</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>The Epstein–Barr virus BILF1 gene encodes a G protein-coupled receptor that inhibits phosphorylation of RNA-dependent protein kinase</article-title>
          <source>J. Virol.</source>
          <volume>79</volume>
          <year>2005</year>
          <fpage>441</fpage>
          <lpage>449</lpage>
          <pub-id pub-id-type="pmid">15596837</pub-id>
        </element-citation>
      </ref>
      <ref id="bib59">
        <label>59</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Paulsen</surname>
              <given-names>S.J.</given-names>
            </name>
            <name>
              <surname>Rosenkilde</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Eugen-Olsen</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Kledal</surname>
              <given-names>T.N.</given-names>
            </name>
          </person-group>
          <article-title>Epstein–Barr virus-encoded BILF1 is a constitutively active G protein-coupled receptor</article-title>
          <source>J. Virol.</source>
          <volume>79</volume>
          <year>2005</year>
          <fpage>536</fpage>
          <lpage>546</lpage>
          <pub-id pub-id-type="pmid">15596846</pub-id>
        </element-citation>
      </ref>
      <ref id="bib60">
        <label>60</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rosenkilde</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Benned-Jensen</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Andersen</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Holst</surname>
              <given-names>P.J.</given-names>
            </name>
            <name>
              <surname>Kledal</surname>
              <given-names>T.N.</given-names>
            </name>
            <name>
              <surname>Luttichau</surname>
              <given-names>H.R.</given-names>
            </name>
            <name>
              <surname>Larsen</surname>
              <given-names>J.K.</given-names>
            </name>
            <name>
              <surname>Christensen</surname>
              <given-names>J.P.</given-names>
            </name>
            <name>
              <surname>Schwartz</surname>
              <given-names>T.W.</given-names>
            </name>
          </person-group>
          <article-title>Molecular pharmacological phenotyping of EBI2. An orphan seven-transmembrane receptor with constitutive activity</article-title>
          <source>J. Biol. Chem.</source>
          <volume>281</volume>
          <year>2006</year>
          <fpage>13199</fpage>
          <lpage>13208</lpage>
          <pub-id pub-id-type="pmid">16540462</pub-id>
        </element-citation>
      </ref>
      <ref id="bib61">
        <label>61</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vischer</surname>
              <given-names>H.F.</given-names>
            </name>
            <name>
              <surname>Nijmeijer</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Smit</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Leurs</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Viral hijacking of human receptors through heterodimerization</article-title>
          <source>Biochem. Biophys. Res. Commun.</source>
          <volume>377</volume>
          <year>2008</year>
          <fpage>93</fpage>
          <lpage>97</lpage>
          <pub-id pub-id-type="pmid">18823943</pub-id>
        </element-citation>
      </ref>
      <ref id="bib62">
        <label>62</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bodaghi</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>T.R.</given-names>
            </name>
            <name>
              <surname>Zipeto</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Vita</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Laurent</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Arenzana-Seisdedos</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Virelizier</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Michelson</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Chemokine sequestration by viral chemoreceptors as a novel viral escape strategy: withdrawal of chemokines from the environment of cytomegalovirus-infected cells</article-title>
          <source>J. Exp. Med.</source>
          <volume>188</volume>
          <year>1998</year>
          <fpage>855</fpage>
          <lpage>866</lpage>
          <pub-id pub-id-type="pmid">9730887</pub-id>
        </element-citation>
      </ref>
      <ref id="bib63">
        <label>63</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Milne</surname>
              <given-names>R.S.</given-names>
            </name>
            <name>
              <surname>Mattick</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Nicholson</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Devaraj</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Alcami</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Gompels</surname>
              <given-names>U.A.</given-names>
            </name>
          </person-group>
          <article-title>RANTES binding and down-regulation by a novel human herpesvirus-6 beta chemokine receptor</article-title>
          <source>J. Immunol.</source>
          <volume>164</volume>
          <year>2000</year>
          <fpage>2396</fpage>
          <lpage>2404</lpage>
          <pub-id pub-id-type="pmid">10679075</pub-id>
        </element-citation>
      </ref>
      <ref id="bib64">
        <label>64</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stern</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Slobedman</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>Human cytomegalovirus latent infection of myeloid cells directs monocyte migration by up-regulating monocyte chemotactic protein-1</article-title>
          <source>J. Immunol.</source>
          <volume>180</volume>
          <year>2008</year>
          <fpage>6577</fpage>
          <lpage>6585</lpage>
          <pub-id pub-id-type="pmid">18453576</pub-id>
        </element-citation>
      </ref>
      <ref id="bib65">
        <label>65</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hirsch</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Shenk</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Human cytomegalovirus inhibits transcription of the CC chemokine MCP-1 gene</article-title>
          <source>J. Virol.</source>
          <volume>73</volume>
          <year>1999</year>
          <fpage>404</fpage>
          <lpage>410</lpage>
          <pub-id pub-id-type="pmid">9847345</pub-id>
        </element-citation>
      </ref>
      <ref id="bib66">
        <label>66</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Qiao</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Watson</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Fan</surname>
              <given-names>G.H.</given-names>
            </name>
          </person-group>
          <article-title>Activation of CXCR4 triggers ubiquitination and down-regulation of major histocompatibility complex class I (MHC-I) on epithelioid carcinoma HeLa cells</article-title>
          <source>J. Biol. Chem.</source>
          <volume>283</volume>
          <year>2008</year>
          <fpage>3951</fpage>
          <lpage>3959</lpage>
          <pub-id pub-id-type="pmid">18083706</pub-id>
        </element-citation>
      </ref>
      <ref id="bib67">
        <label>67</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schwartz</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Marechal</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Le Gall</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Lemonnier</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Heard</surname>
              <given-names>J.M.</given-names>
            </name>
          </person-group>
          <article-title>Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein</article-title>
          <source>Nat. Med.</source>
          <volume>2</volume>
          <year>1996</year>
          <fpage>338</fpage>
          <lpage>342</lpage>
          <pub-id pub-id-type="pmid">8612235</pub-id>
        </element-citation>
      </ref>
      <ref id="bib68">
        <label>68</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kasper</surname>
              <given-names>M.R.</given-names>
            </name>
            <name>
              <surname>Collins</surname>
              <given-names>K.L.</given-names>
            </name>
          </person-group>
          <article-title>Nef-mediated disruption of HLA-A2 transport to the cell surface in T cells</article-title>
          <source>J. Virol.</source>
          <volume>77</volume>
          <year>2003</year>
          <fpage>3041</fpage>
          <lpage>3049</lpage>
          <pub-id pub-id-type="pmid">12584329</pub-id>
        </element-citation>
      </ref>
      <ref id="bib69">
        <label>69</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Le Gall</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Buseyne</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Trocha</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Walker</surname>
              <given-names>B.D.</given-names>
            </name>
            <name>
              <surname>Heard</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Schwartz</surname>
              <given-names>O.</given-names>
            </name>
          </person-group>
          <article-title>Distinct trafficking pathways mediate Nef-induced and clathrin-dependent major histocompatibility complex class I down-regulation</article-title>
          <source>J. Virol.</source>
          <volume>74</volume>
          <year>2000</year>
          <fpage>9256</fpage>
          <lpage>9266</lpage>
          <pub-id pub-id-type="pmid">10982373</pub-id>
        </element-citation>
      </ref>
      <ref id="bib70">
        <label>70</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lubben</surname>
              <given-names>N.B.</given-names>
            </name>
            <name>
              <surname>Sahlender</surname>
              <given-names>D.A.</given-names>
            </name>
            <name>
              <surname>Motley</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Lehner</surname>
              <given-names>P.J.</given-names>
            </name>
            <name>
              <surname>Benaroch</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Robinson</surname>
              <given-names>M.S.</given-names>
            </name>
          </person-group>
          <article-title>HIV-1 Nef-induced down-regulation of MHC class I requires AP-1 and clathrin but not PACS-1 and is impeded by AP-2</article-title>
          <source>Mol. Biol. Cell</source>
          <volume>18</volume>
          <year>2007</year>
          <fpage>3351</fpage>
          <lpage>3365</lpage>
          <pub-id pub-id-type="pmid">17581864</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <ack>
      <title>Acknowledgments</title>
      <p>We thank Dr Britt Glaunsinger for allowing us access to some of her unpublished data. The work of the authors was supported by grants from the Wellcome Trust and the Medical Research Council.</p>
    </ack>
  </back>
  <floats-group>
    <fig id="fig1">
      <label>Fig. 1</label>
      <caption>
        <p>Schematic comparing the modulation of HLA-I antigen presentation by (A) HCMV and (B) EBV gene products.</p>
      </caption>
      <graphic xlink:href="gr1"/>
    </fig>
    <fig id="fig2">
      <label>Fig. 2</label>
      <caption>
        <p>Residues in BGLF5 that, when mutated, affect both DNase and host-shutoff function (D203S; red), or selectively affect DNase (S280L; blue) or shutoff functions (K231M; yellow). The purple shaded regions of the BGLF5 cartoon structure represent the DNase catalytic core. The green shaded regions are the non-catalytic core domains mainly comprising the N-terminal domains, where in mutations selective for shutoff function are clustered in the KSHV SOX protein <xref rid="bib56" ref-type="bibr">[56]</xref>. The structure of the BGLF5 protein was taken from PDB ID: 2W45 <xref rid="bib49" ref-type="bibr">[49]</xref> (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article).</p>
      </caption>
      <graphic xlink:href="gr2"/>
    </fig>
  </floats-group>
</article>